Lebeer, S., Vanderleyden, J
Both drugs demonstrate superior results in glycemic control, weight reduction, and cardiovascular risk management, compared to conventional therapies
There is clinical proof that using GLP-1 peptide Cagrilintide with GLP-1 receptor agonists makes it work better without raising too many safety issues
Our cGMP-certified facilities deliver 99.5% purity products with comprehensive regulatory documentation supporting global market access
doi: 10.1038/s41591-024-02996-7 Summary Keywords semaglutide, arrhythmic, cardiovascular, microvascular, type 2 diabetes, meta-analysis Citation Wu R, Xing B, Huang Y, Zhou Z, Sun B, Yu L and Wang H (2025) Effect of semaglutide on arrhythmic, major cardiovascular, and microvascular outcomes in patients with type 2 diabetes: a systematic review and meta-analysis